TUMOR NECROSIS FACTOR (TNF) BLOCKER
Ixifi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat people with rheumatoid arthritis in combination with methotrexate. Ixifi is also indicated to treat Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Ixifi is also referred to by its drug name, infliximab-qbtx.
Ixifi is a member of a class of drugs called tumor necrosis factor (TNF) blockers. Ixifi is believed to work by binding to and inhibiting TNF-alpha, reducing the normal functions of TNF including inflammation and immune response. Ixifi is biologically similar to the FDA-approved drug Remicade (infliximab).
How do I take it?
Prescribing information states that Ixifi is administered as an intravenous infusion once every several weeks according to the physician’s recommendation.
Ixifi comes in injectable form.
The FDA-approved label for Ixifi lists common side effects including infections, headaches, reactions to the infusion, and abdominal pain.
Rare but serious side effects listed for Ixifi include serious infections, cancer, reactivation of hepatitis B virus, liver disease, heart failure and other serious heart problems, low white blood cell counts, allergic reaction to the infusion, lupus-like syndrome, and demyelinating disease (a disease of the nervous system).
For more details about this treatment, visit:
Ixifi — Pfizer
Ixifi — RxList